Table 1

Patient characteristicsa

Early breast cancer

Metastatic breast cancer


Number of patients enrolled = 25

Number of patients enrolled = 25

Age, years

Age, years

Median (range), 59 (26 to 76)

Median (range), 59 (36 to 83)

ECOG performance status, n (%)

ECOG performance status, n (%)

0 24 (96%)

0 8 (32%)

1 1 (4%)

1 13 (52%)

2 0 (0%)

2 4 (16%)

Histology, n (%)

Histology, n (%)

Ductal 22 (88%)

Ductal 20 (80%)

Lobular 3 (12%)

Lobular 1 (4%)

Other 0 (0%)

Unknown 4 (16%)

Menopausal status, n (%)

Menopausal status, n (%)

Premenopausal 8 (32%)

Premenopausal 4 (16%)

Perimenopausal 1 (4%)

Perimenopausal 1 (4)

Postmenopausal 16 (64%)

Postmenopausal 20 (80%)

Hormone receptor status, n (%)

Hormone receptor status, n (%)

ER-positive/PR-positive 11 (44%)

ER-positive/PR-positive 11 (44%)

ER-positive/PR-negative 6 (24%)

ER-positive/PR-negative 3 (12%)

ER-negative/PR-positive 1 (4%)

ER-negative/PR-positive 2 (8%)

ER-negative/PR-negative 7 (28%)

ER-negative/PR-negative 9 (36%)

Tumour size, n (%)

Number of disease sites, n (%)

1 to 1.9 cm (T1) 6 (24%)

1 7 (28%)

2 to 5 cm (T2) 16 (64%)

2 9 (36%)

>5 cm (T3) 1 (4%)

3 4 (16%)

Unknown 2 (8%)

≥4 5 (20%)

Tumour grade, n (%)

Line of treatment, n (%)

I 2 (8%)

First 11 (44%)

II 9 (36%)

Second 7 (28%)

III 13 (52%)

≥Third 7 (28%)

Unknown 1 (4%)

Primary breast cancer at presentation, n (%)

Early 9 (36%)

Positive nodes, n (%)

Metastatic 16 (64%)

0 (N0) 11 (44%)

1 to 3 (N1) 9 (36%)

Visceral disease, n (%)

4 to 9 (N2) 2 (8%)

Yes 13 (52%)

≥10 (N3) 2 (8%)

No 12 (48%)


aECOG = Eastern Cooperative Oncology Group; ER = oestrogen receptor; PR = progesterone receptor.

Kallergi et al. Breast Cancer Research 2011 13:R59   doi:10.1186/bcr2896

Open Data